Key facts
- This page summarizes Marc Antonius van Dijk's Form 4 filing for MiNK Therapeutics, Inc. (INKT).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 18 Jan 2024, 20:00.
Marc Antonius van Dijk - 16 Jan 2024 Form 4 Insider Report for MiNK Therapeutics, Inc. (INKT)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- INKT
- Reported as of
- 16 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Jan 2024, 20:00:08 UTC
- Prior SEC filing
- 12 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Christine Klaskin, Attorney-in-Fact for Marc Antonius van Dijk
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Marc Antonius van Dijk filed Form 4 for MiNK Therapeutics, Inc. (INKT) on 18 Jan 2024.
Change
- Previous filing in this sequence was filed on 12 Jan 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INKT
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +15,000
- Change %
- Price
- $0.000000
- Shares after
- 15,000
- Date
- 16 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $0.8700
- Footnotes
- F1
INKT
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +171,078
- Change %
- Price
- $0.000000
- Shares after
- 171,078
- Date
- 16 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 171,078
- Exercise price
- $0.8700
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
An option to purchase Common Stock was granted to Dr. van Dijk on January 16, 2024 and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. The option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter.
Footnote F2
An option to purchase Common Stock was granted to Dr. van Dijk on January 16, 2024 for his performance in 2023, and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. Half of the options will vest on June 27, 2024 and half of the options will vest on September 27, 2024.